Highlighted papers are below, but a complete list is available here.

Fu C, Saddawi-Konefka R, Chinai JM, Kim SY, Kammula AV, Perera JJ, Jiang A, Tiwari P, Kistler EN, Tang S, Luna SM, Colvin KJ, Dubrot J, Anderson S, Fetterman RA, Chuong CL, Lane-Reticker SK, Cheruiyot CK, Muscato AJ, Alipour Z, Adkins DR, Griffin GK, Bernstein BE, Egloff AM, Yates KB, Chernock RD, Gutkind JS, Uppaluri R*, Manguso RT*. In vivo CRISPR screening in head and neck cancer reveals Uchl5 as an immunotherapy target. Nat Commun. 2025 Sep 29;16(1):8572. doi: 10.1038/s41467-025-63592-y.

Knudsen NH*, Escobar G*, Korell F*, Kienka T, Nobrega C, Anderson S, Cheng AY, Zschummel M, Armstrong A, Bouffard A, Kann MC, Goncalves S, Pope HW, Pezeshki M, Rojas A, Suermondt JSMT, Phillips M, Berger TR, Park S, Salas-Benito D, Darnell EP, Birocchi F, Leick MB, Larson RC, Doench JG, Sen D, Yates KB, Manguso RT*, Maus MV*. In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma. Nature. 2025 Oct;646(8086):953-962. doi: 10.1038/s41586-025-09489-8.

Tsao HW*, Anderson S*, Finn KJ*, Perera JJ, Pass LF, Schneider EM, Jiang A, Fetterman R, Chuong CL, Kozuma K, Stickler MM, Creixell M, Klaeger S, Phulphagar KM, Rachimi S, Verzani EK, Olsson N, Dubrot J, Pech MF, Silkworth W, Lane-Reticker SK, Allen PM, Ibrahim K, Knudsen NH, Cheng AY, Long AH, Ebrahimi-Nik H, Kim SY, Du PP, Iracheta-Vellve A, Robitschek EJ, Suermondt JSMT, Davis TGR, Wolfe CH, Atluri T, Olander KE, Rush JS, Sundberg TB, McAllister FE, Abelin JG, Firestone A, Stokoe D, Carr SA, Harding FA, Yates KB*, Manguso RT*. Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. Immunity. 2024 Dec 10;57(12):2863-2878.e12. doi: 10.1016/j.immuni.2024.10.013.

Wu MJ*, Kondo H*,, Kammula AV*, Shi L, Xiao Y, Dhiab S, Xu Q, Slater CJ, Avila OI, Merritt J, Kato H, Kattel P, Sussman J, Gritti I, Eccleston J, Sun Y, Cho HM, Olander K, Katsuda T, Shi DD, Savani MR, Smith BC, Cleary JM, Mostoslavsky R, Vijay V, Kitagawa Y, Wakimoto H, Jenkins RW, Yates KB, Paik J, Tassinari A, Saatcioglu DH, Tron AE, Haas W, Cahill D, McBrayer SK, Manguso RT*, Bardeesy N*,. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science. 2024 Jul 12;385(6705):eadl6173. doi: 10.1126/science.adl6173.

Christina K. Baumgartner*, Hakimeh Ebrahimi-Nik*, Arvin Iracheta-Vellve, Keith M. Hamel, Kira E. Olander, Thomas G. R. Davis, Kathleen A. McGuire, Geoff T. Halvorsen, Omar I. Avila, Chirag H. Patel, Sarah Y. Kim, Ashwin V. Kammula, Audrey J. Muscato, Kyle Halliwill, Prasanthi Geda, Kelly L. Klinge, Zhaoming Xiong, Ryan Duggan, Liang Mu, Mitchell D. Yeary, James C. Patti, Tyler M. Balon, Rebecca Mathew, Carey Backus, Domenick E. Kennedy, Angeline Chen, Kenton Longenecker, Joseph T. Klahn, Cara L. Hrusch, Navasona Krishnan, Charles W. Hutchins, Jax P. Dunning, Marinka Bulic, Payal Tiwari, Kayla J. Colvin, Cun Lan Chuong, Ian C. Kohnle, Matthew G. Rees, Andrew Boghossian, Melissa Ronan, Jennifer A. Roth, Meng-Ju Wu, Juliette S. M. T. Suermondt, Nelson H. Knudsen, Collins K. Cheruiyot, Debattama R. Sen, Gabriel K. Griffin, Todd R. Golub, Nabeel El-Bardeesy, Joshua H. Decker, Yi Yang, Magali Guffroy, Stacey Fossey, Patricia Trusk, Im-Meng Sun, Yue Liu, Wei Qiu, Qi Sun, Marcia N. Paddock, Elliot P. Farney, Mark A. Matulenko, Clay Beauregard, Jennifer M. Frost*, Kathleen B. Yates*, Philip R. Kym* & Manguso RT*. The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity. Nature 622, 850–862 (2023). https://doi.org/10.1038/s41586-023-06575-7

Dubrot J*, Du PP*, Lane-Reticker SK, Kessler EA, Muscato AJ, Mehta A, Freeman SS, Allen PM, Olander KE, Ockerman KM, Wolfe CH, Wiesmann F, Knudsen NH, Tsao HW, Iracheta-Vellve A, Schneider EM, Rivera-Rosario AN, Kohnle IC, Pope HW, Ayer A, Mishra G, Zimmer MD, Kim SY, Mahapatra A, Ebrahimi-Nik H, Frederick DT, Boland GM, Haining WN, Root DE, Doench JG, Hacohen N, Yates KB*, Manguso RT*. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nature Immunology. 2022 Oct;23(10):1495-1506. doi: 10.1038/s41590-022-01315-x.

Griffin GK*, Wu J*, Iracheta-Vellve A*, Patti JC, Hsu J, Davis TGR, Dele-Oni D, Du PP, Halawi AG, Ishizuka JJ, Kim SY, Klaeger S, Knudsen NH, Miller BM, Nguyen TH, Olander KE, Papanastasiou M, Rachimi S, Robitschek EJ, Schneider EM, Yeary MD, Zimmer MD, Jaffe JD, Carr SA, Doench JG, Haining WN, Yates KB, Manguso RT*, Bernstein BE*. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature. 2021 Jul;595(7866):309-314. doi: 10.1038/s41586-021-03520-4.

Dubrot J*, Lane-Reticker SK*, Kessler EA, Ayer A, Mishra G, Wolfe CH, Zimmer MD, Du PP, Mahapatra A, Ockerman KM, Davis TGR, Kohnle IC, Pope HW, Allen PM, Olander KE, Iracheta-Vellve A, Doench JG, Haining WN, Yates KB*, Manguso RT*. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. Immunity. 2021 Mar 9;54(3):571-585. doi: 10.1016/j.immuni.2021.01.001.

Ishizuka JJ*, Manguso RT*, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A, Miller BC, Du PP, Yates KB, Dubrot J, Buchumenski I, Comstock DE, Brown FD, Ayer A, Kohnle IC, Pope HW, Zimmer MD, Sen DR, Lane-Reticker SK, Robitschek EJ, Griffin GK, Collins NB, Long AH, Doench JG, Kozono D, Levanon EY, Haining WN. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature. 2019 Jan;565(7737):43-48. doi: 10.1038/s41586-018-0768-9.

Lane-Reticker SK, Manguso RT, Haining WN. Pooled in vivo screens for cancer immunotherapy target discovery. Immunotherapy. 2018 Mar;10(3):167-170. doi: 10.2217/imt-2017-0164.

Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, Collins NB, Bi K, LaFleur MW, Juneja VR, Weiss SA, Lo J, Fisher DE, Miao D, Van Allen E, Root DE, Sharpe AH, Doench JG, Haining WN. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017 Jul 27;547(7664):413-418. doi: 10.1038/nature23270.